Home › Atopic Dermatitis (Eczema) › Michigan
Pag-aaral pangklinika para sa Atopic Dermatitis (Eczema) sa Michigan
13 pag-aaral para sa Atopic Dermatitis (Eczema) ang naghahanap ng mga kalahok sa mga site sa Michigan.
Mga Lungsod sa Michigan
Opisyal na teksto ng pag-aaral (English)
Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project
- University of Michigan, Ann Arbor
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
Edad 10 hanggang 55 · Lahat ng kasarian · Na-update Nob 10, 2026 · NCT06300697Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
- Derm Research Institute, PLC, Caledonia
Nagre-recruitObservasyonal na pag-aaral
Edad 12 hanggang 89 · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT07645820A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Leo Pharma Investigational site, Waterford
Nagre-recruitPhase 3
6 Months – 11 Years · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT06311682A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
- Revival Research Institute, LLC, Troy
- Respiratory Medicine Research Institute of Michigan, PLC, Ypsilanti
Nagre-recruitPhase 3
Edad 12 pataas · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT07783425FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- Revival Research Institute, LLC, Troy
Nagre-recruitPhase 1Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Nob 5, 2026 · NCT06564389A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
- Investigational Site, Detroit
- Investigational Site, Troy
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT07003425This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- David Fivenson, MD, Dermatology, PLLC- Site Number : 8400017, Ann Arbor
- Oakland Hills Dermatology- Site Number : 8400042, Auburn Hills
- Great Lakes Research Group - Bay City- Site Number : 8400052, Bay City
- at 3 pa
Nagre-recruitObservasyonal na pag-aaral
Edad 12 pataas · Lahat ng kasarian · Na-update Nob 2, 2026 · NCT07290803A Study Evaluating TRIV-573 in Atopic Dermatitis
- Triveni Bio Site #13, Bay City
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Okt 28, 2026 · NCT07782333Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Troy
Nagre-recruitPhase 2
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06947993Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Auburn Hills
- Enveda Investigative Site, Bay City
- Enveda Investigative Site, Clinton Township
- at 1 pa
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07298395Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 7066, Auburn Hills
- Galderma Investigational Site 7071, Caledonia
- Galderma Investigational Site 7108, Grandville
- at 1 pa
Nagre-recruitObservasyonal na pag-aaral
Edad 12 pataas · Lahat ng kasarian · Na-update Mar 13, 2026 · NCT06988605Ethnic Differences in Mechanisms of Action of Dupilumab
- University of Michigan, Ann Arbor
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 6, 2025 · NCT05268107A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
- University of Michigan Health System - Ann Arbor /ID# 267275, Ann Arbor
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Ene 24, 2025 · NCT06524635Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.